Compare CLW & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | SGHT |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.4M | 235.0M |
| IPO Year | 2008 | 2021 |
| Metric | CLW | SGHT |
|---|---|---|
| Price | $13.64 | $4.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.33 | $9.08 |
| AVG Volume (30 Days) | 186.0K | ★ 331.1K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | $4.16 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $3.11 |
| 52 Week High | $30.96 | $9.24 |
| Indicator | CLW | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 56.02 |
| Support Level | $12.09 | $3.29 |
| Resistance Level | $14.56 | $5.46 |
| Average True Range (ATR) | 0.74 | 0.41 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 64.31 | 55.88 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.